Neuroone Medical Technologies (NMTC) Return on Equity (2011 - 2026)

Neuroone Medical Technologies has disclosed Return on Equity across 15 years of filings, most recently posting 0.01% for Q1 2026.

• Quarterly Return on Equity rose 2.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 2.0% YoY) and the FY2025 annual result came in at 0.01%, up 3.0% from the prior year.
• Return on Equity retreated to 0.01% in Q1 2026, from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q3 2025 and bottomed at 0.06% in Q3 2024.
• The 5-year median for Return on Equity is 0.01% (2023), against an average of 0.02%.
• Year-over-year, Return on Equity declined 4 bps in 2024 and advanced 6 bps in 2025.
• Neuroone Medical Technologies' Return on Equity stood at 0.01% in 2022, then sank by 152 bps to 0.03% in 2023, then sank by 51 bps to 0.04% in 2024, then surged by 74 bps to 0.01% in 2025, then slipped by 19 bps to 0.01% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.01%, 0.01%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.